Profound Medical (PROF) Financials

Profound Medical’s Q2 2026 results show improving gross margins and lower year-over-year losses, but the company continues to consume significant cash and remains far from profitability. Revenue was $2.5 million, up approximately 12% from $2.2 million in Q2 2025, while gross profit increased to $1.9 million. Gross margin improved to roughly 78%, compared with approximately 73% a year earlier.

Operating expenses declined to $13.0 million from $15.4 million in Q2 2025, primarily reflecting lower selling, general and administrative costs. However, expenses increased sequentially from $11.9 million in Q1 2026. Profound Medical reported a net loss of $9.5 million, an improvement from the $15.7 million loss recorded in the restated Q2 2025 results, but worse than the $7.1 million loss in Q1 2026.

Cash generation remains the primary concern. Operating cash flow was negative $11.3 million in Q2 2026, compared with negative $8.6 million in Q1 and negative $13.7 million in Q2 2025. Cash and equivalents declined to $38.3 million from $50.3 million at the end of Q1. At the recent quarterly burn rate, the company has limited cash visibility unless operating losses narrow, revenue accelerates or additional capital is raised.

• Revenue and gross margin improved year over year. Q2 revenue increased approximately 12%, while gross margin rose to about 78%, indicating favorable product mix or pricing trends.
• Operating expenses were lower than a year ago. Total operating expenses fell approximately 16% year over year, and SG&A declined from $9.3 million to $7.4 million.
• The quarterly net loss narrowed substantially year over year. The Q2 loss improved to $9.5 million from a restated loss of $15.7 million in Q2 2025.
• Liquidity remains stronger than in mid-2025. Q2 cash of $38.3 million was above the $35.2 million reported at the end of Q2 2025, and current assets of $58.9 million substantially exceeded current liabilities of $9.1 million.
• Debt is relatively modest and concentrated in the short term. Short-term debt was approximately $4.5 million, with no long-term debt reported, limiting interest-rate and refinancing exposure compared with the balance sheet in early 2025.
• Revenue growth has been highly volatile. Quarterly revenue rose from $1.4 million in Q1 2024 to $6.0 million in Q4 2025, but then declined to $2.5 million by Q2 2026. Investors should look for more consistent growth before assuming the recent improvement is durable.
• Research and development spending remains substantial. R&D expense was $5.7 million in Q2, supporting future product development but continuing to weigh heavily on current earnings.
• Profound Medical remains deeply unprofitable. The company has reported recurring quarterly net losses, and retained earnings were negative $304.3 million at June 30, 2026.
• Operating cash burn accelerated sequentially. Q2 operating cash flow was negative $11.3 million, worse than the negative $8.6 million reported in Q1 2026, despite the year-over-year improvement.
• Shareholder dilution is a continuing risk. Weighted-average basic shares increased from approximately 24.3 million in Q1 2024 to 36.4 million in Q2 2026. The company also relied on significant equity issuance in prior quarters, including approximately $42.4 million in Q4 2025.

Overall, the statements show operational progress in gross margin, expense control and year-over-year losses, but not yet a self-sustaining business. The most important factors for investors to monitor are revenue consistency, operating cash burn, progress toward profitability and whether future funding needs result in additional dilution.